Monte Rosa Therapeutics, Inc.
GLUE
$15.50
-$0.34-2.15%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -161.12M | -130.01M | -38.63M | 20.95M | 24.17M |
| Total Depreciation and Amortization | 10.79M | 10.91M | 10.86M | 10.67M | 10.62M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.59M | 14.85M | 14.16M | 13.70M | 13.05M |
| Change in Net Operating Assets | 110.67M | 89.59M | -9.19M | 103.83M | -20.12M |
| Cash from Operations | -24.07M | -14.68M | -22.80M | 149.14M | 27.72M |
| Capital Expenditure | -8.01M | -4.98M | -4.70M | -4.12M | -3.86M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -308.78M | -257.62M | -97.13M | -63.55M | -64.19M |
| Cash from Investing | -316.79M | -262.60M | -101.83M | -67.66M | -68.05M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 383.06M | 380.22M | 30.71M | 1.34M | 1.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -21.54M | -21.54M | -357.00K | 0.00 | 0.00 |
| Cash from Financing | 361.52M | 358.67M | 30.35M | 1.34M | 1.00M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 20.66M | 81.40M | -94.28M | 82.81M | -39.33M |